Results of a phase III trial to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab for first line chronic lymphocytic leukemia.
Home / Resource Library / Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL